Dermatology

Skin cancer checks, eczema/psoriasis, acne care, and cosmetic dermatology news.

  • 4 Tracked terms
  • Last 30 days Feed window
Search within this topic Ask AI about this topic All topics

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Dermatology


pharmaphorum.com > news > fda-approves-lillys-psoriasis-drug-tevas-asthma-treatment

FDA approves Lilly's psoriasis drug, Teva's asthma treatment

18+ min ago   (372+ words) Eli Lilly's Taltz (ixekizumab) has been approved in the US for moderate-to-severe plaque psoriasis, along with Teva's asthma drug Cinqair (reslizumab). Taltz, a rival to Novartis' Cosentyx (secukinumab), could generate sales of $558 million by 2019, according to some analysts. It is…...


pharmaphorum.com > news > lillys-zepbound-enhances-taltz-efficacy-psoriasis-study

Lilly's Zepbound enhances Taltz efficacy in psoriasis study

28+ min ago   (479+ words) A study has shown that the efficacy of Eli Lilly's psoriasis therapy Taltz is improved when it is given in combination with the company's blockbuster weight-loss therapy Zepbound. The results showed that when the two drugs were used together, a…...


medwatch.com > News > Pharma___Biotech > article19727701.ece

Eli Lilly says combining Taltz and Zepbound works better than Taltz alone in psoriasis study

3+ hour, 25+ min ago   (42+ words) Senior Drug Substance Scientist Senior Manager, Finance Business Partner Chef for Kvalitet og Compliance Associate Market Access Director – European Markets Faglig rådgiver til ATMP Danmark Senior Project Manager DD&T Head of Medical Affairs International Markets Associate Market Access Director…...


jnj.com > media-center > press-releases > new-johnson-johnson-icotyde-icotrokinra-long-term-data-demonstrate-robust-2-year-results-in-the-treatment-of-adults-and-adolescents-with-plaque-psoriasis

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

2+ day, 19+ hour ago   (687+ words) Learn about our healthcare areas Find our latest news, stories and press releases Delivering long-term value for our stakeholders Explore career opportunities and more Impacting health for humanity Sorry, I don't understand. Please try again Spring House, Pa. (October 9, 2026) – Johnson…...


thedermdigest.com > biofrontera-submits-snda-to-expand-ameluz-pdt-for-aks-across-the-body

Biofrontera Submits sNDA to Expand Ameluz PDT for AKs Across the Body

7+ hour, 35+ min ago   (462+ words) The Dermatology Digest Biofrontera Submits sNDA to Expand Ameluz PDT for AKs Across the Body Ameluz PDT is currently FDA approved for AKs on the face and scalp and, since September 2026, for superficial basal cell carcinoma (sBCC). If approved, the…...


bioengineer.org > rna-sensor-mda5-emerges-as-a-surprising-ally-of-tumors-against-immune-attack

RNA Sensor MDA5 Emerges as a Surprising Ally of Tumors Against Immune Attack

2+ hour, 6+ min ago   (590+ words) Bioengineer.org...


geneticliteracyproject.org > 10/12/2026 > personalized-mrna-vaccines-are-poised-to-revolutionize-cancer-treatments-here-are-the-barriers

Personalized mRNA vaccines are poised to revolutionize cancer treatments. Here are the barriers.

6+ hour, 30+ min ago   (233+ words) Personalized mRNA vaccines that train the immune system to hunt a patient’s own tumor mutations are nearing approval, but, as Pharma Voice’s Alexandra Pecci reports, building them may prove harder than discovering them. Merck and Moderna’s melanoma vaccine, intismeran autogene,…...


hcplive.com > view > fda-approves-bimekizumab-adults-with-hidradenitis-suppurativa

FDA Approves Bimekizumab for Adults with Hidradenitis Suppurativa

7+ hour, 1+ min ago   (295+ words) UCB has announced the FDA’s approval of bimekizumab, also known as Bimzelx, for patients with moderate-to-severe HS. This treatment is a humanized IgG1 monoclonal antibody. It is distinct as it is the first and only medication specifically formulated with the aim…...


bioengineer.org > quality-of-life-test-for-skin-disease-fails-to-outperform-its-rival-in-new-study

Quality-of-Life Test for Skin Disease Fails to Outperform Its Rival in New Study

4+ hour, 7+ min ago   (77+ words) Bioengineer.org Subject of Research: Comparison of DLQI and DLQI-Relevant quality-of-life scores against disease severity in psoriasis and chronic urticaria Article Title: The relationship between DLQI and DLQI-R scores and disease severity in patients with active psoriasis and chronic urticaria:…...


dermatologytimes.com > shorts > a-new-approach-to-managing-actinic-keratoses

A New Approach to Managing Actinic Keratoses

10+ hour, 43+ min ago   (106+ words) Neal Bhatia, MD, dermatologist and director of clinical dermatology at Therapeutic Clinical Research in San Diego, California, recently spoke with Dermatology Times about the highlights of his sessions at Fall Clinical 2026. He covered comprehensive management of actinic keratosis, a new…...